DURHAM, N.C. — Inspire Pharmaceuticals is preparing to launch Phase 2 clinical trials for a proposed allergy drug treatment.
The drug, called epinastine, is intended to counter seasonal allergic rhinitis. Symptoms include nasal congestion, runny nose and nasal itching.
Inspire also said it would file an investigational new drug application (IND) with the Food and Drug Administration. The decisions to move forward with epinastine followed a preliminary IND meeting with the FDA.
The company plans to file the IND in the third quarter of this year and launch the clinical trial involving between 600-700 subjects with seasonal allergies before the end of the year.